Lineage Cell Therapeutics Stock Fundamentals
| LCTX Stock | USD 0.57 0.04 6.56% |
Lineage Cell Therapeutics fundamentals help investors to digest information that contributes to Lineage Cell's financial success or failures. It also enables traders to predict the movement of Lineage Stock. The fundamental analysis module provides a way to measure Lineage Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lineage Cell stock.
At this time, Lineage Cell's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 6 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 20.7 M in 2024. Lineage | Select Account or Indicator |
Lineage Cell Therapeutics Company Return On Asset Analysis
Lineage Cell's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lineage Cell Return On Asset | -0.13 |
Most of Lineage Cell's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lineage Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Lineage Total Assets
Total Assets |
|
Based on the latest financial disclosure, Lineage Cell Therapeutics has a Return On Asset of -0.1286. This is 98.53% lower than that of the Biotechnology sector and 99.46% lower than that of the Health Care industry. The return on asset for all United States stocks is 8.14% lower than that of the firm.
Lineage Cell Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lineage Cell's current stock value. Our valuation model uses many indicators to compare Lineage Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lineage Cell competition to find correlations between indicators driving Lineage Cell's intrinsic value. More Info.Lineage Cell Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Lineage Cell's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lineage Cell's earnings, one of the primary drivers of an investment's value.Lineage Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lineage Cell's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lineage Cell could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics of similar companies.Lineage Cell is currently under evaluation in return on asset category among its peers.
Lineage Fundamentals
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | 96.1 M | ||||
| Shares Outstanding | 220.42 M | ||||
| Shares Owned By Insiders | 0.44 % | ||||
| Shares Owned By Institutions | 50.56 % | ||||
| Number Of Shares Shorted | 15.94 M | ||||
| Price To Earning | 3.62 X | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 20.38 X | ||||
| Revenue | 8.95 M | ||||
| Gross Profit | 13.97 M | ||||
| EBITDA | (24.04 M) | ||||
| Net Income | (21.49 M) | ||||
| Cash And Equivalents | 66.36 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 2.95 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 3.01 X | ||||
| Book Value Per Share | 0.36 X | ||||
| Cash Flow From Operations | (28.57 M) | ||||
| Short Ratio | 35.21 X | ||||
| Earnings Per Share | (0.10) X | ||||
| Target Price | 4.5 | ||||
| Number Of Employees | 68 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 126.06 M | ||||
| Total Asset | 101.02 M | ||||
| Retained Earnings | (384.86 M) | ||||
| Working Capital | 20.48 M | ||||
| Current Asset | 12.84 M | ||||
| Current Liabilities | 2.74 M | ||||
| Net Asset | 101.02 M |
About Lineage Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lineage Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 10.8 M | 11.3 M | |
| Total Revenue | 8.9 M | 9.4 M | |
| Cost Of Revenue | 671 K | 583.4 K | |
| Stock Based Compensation To Revenue | 0.52 | 0.49 | |
| Sales General And Administrative To Revenue | 1.93 | 1.84 | |
| Research And Ddevelopement To Revenue | 1.76 | 1.67 | |
| Capex To Revenue | 0.08 | 0.07 | |
| Revenue Per Share | 0.05 | 0.03 | |
| Ebit Per Revenue | (2.77) | (2.90) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.